var data={"title":"Carboplatin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Carboplatin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5822?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">see &quot;Carboplatin: Drug information&quot;</a> and <a href=\"topic.htm?path=carboplatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Carboplatin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708661\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Carboplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Bone marrow suppression is dose related and may be severe, resulting in infection or bleeding. Anemia may be cumulative and may require transfusion support. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Vomiting:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Vomiting is a frequent drug-related side effect.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of carboplatin administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146189\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Carboplatin Injection;</li>\n      <li>Carboplatin Injection BP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045745\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Alkylating Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Platinum Analog</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045738\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">see &quot;Carboplatin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol. In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>), weight (mg/<b>kg</b>), or a modified Calvert formula calculation (mg); use extra precaution to verify dosing parameters and units of GFR/estimated CrCl during calculations, as errors can lead to significant over/under dosing. Some protocols suggest weight or age cut-offs for weight-based (mg/kg) dosing; refer to specific protocol. Carboplatin is associated with a high emetic potential in pediatric patients (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Calvert Formula, modified:</b> Limited data available; multiple formulas have been used; formula may be protocol-specific (Liem 2003): Some protocols may calculate pediatric carboplatin doses using one of the following modified Calvert formulas:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption>Modified Calvert Formulas</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <tbody>\n        <tr>\n          <td colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;margin-top:2em;text-align:left;\">Target AUC: Protocol specific dependent upon indication; value presented in terms of mg/mL and minute units (eg, mg/mL/minute or mg/mL&#8729;minute are frequently reported).</p>\n            <p style=\"text-indent:0em;margin-top:2em;text-align:left;\">\n              <b>Note:</b> Ensure appropriate GFR value<sup>A</sup> is used for calculation and resulting carboplatin dose (mg or mg/m<sup>2</sup>) units.</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Newell formula</p>\n            <p style=\"text-indent:0em;\">(Newell 1993)</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Total dose (mg) =</b> Target AUC x [uncorrected or raw GFR (mL/minute) + (0.36 x kg body weight)]</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Mann/Pein formula</p>\n            <p style=\"text-indent:0em;\">(Mann 1998; Mann 2000; Pein 1998)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <b>Total dose (mg)</b> = Target AUC x [uncorrected or raw GFR (mL/minute) + (15 x BSA(m<sup>2</sup>))]</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Marina/St. Jude formula<sup>B</sup></p>\n            <p style=\"text-indent:0em;\">(Allen 2010; Marina 1993)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">\n              <b>Dose (mg/m<sup>2</sup>)</b> = Target AUC x [(0.93 x corrected GFR normalized to patient&rsquo;s BSA (mL/minute/m<sup>2 </sup><sup></sup>)) + 15]</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">\n              <sup>A</sup>GFR definitions:</p>\n            <p style=\"text-indent:-2em;margin-left:4em;text-align:left;\">Raw GFR = uncorrected GFR = mL/minute</p>\n            <p style=\"text-indent:-2em;margin-left:4em;text-align:left;\">Normalized GFR = corrected GFR = mL/minute/1.73 m<sup>2</sup></p>\n            <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:left;\">\n              <sup>B</sup>Marina/St. Jude formula: Uses a corrected GFR normalized to patient&rsquo;s BSA (mL/minute/m<sup>2</sup>); converting GFR to this may be done as follows:</p>\n            <p style=\"text-indent:-2em;margin-left:4em;text-align:left;\">Corrected GFR (mL/minute/1.73 m<sup>2</sup>)/1.73 = GFR (mL/minute/m<sup>2</sup>)</p>\n            <p style=\"text-indent:-2em;margin-left:4em;text-align:left;\">Uncorrected GFR (mL/minute)/patient&rsquo;s BSA = GFR (mL/minute/m<sup>2</sup>)</p></td></tr></tbody></table>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Calvert formula was based on using chromic edetate (51Cr-EDTA) plasma clearance to establish GFR. This or 99mTc- DTPA nuclear medicine GFR study is preferred over estimating CrCl per Schwartz equation as CrCl theoretically exceeds measured GFR by &gt;12% in subjects with normal renal function (Allen 2010) (see Warnings/Precautions for additional information).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematopoietic stem cell transplant (HSCT):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cohen 2015:</i> Consolidation with myeloablative chemotherapy: Infants &ge;6 months and Children &le;3 years: IV: 17 mg/<b>kg</b> over 2 hours on days 0 and 1 of a 21-day cycle in combination with thiotepa for 3 cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Gilheeney 2010, Kushner 2001:</i> Myeloablative: Children and Adolescents: IV: ~500 mg/m<sup>2</sup> over 4 hours for 3 doses on days -5 to -3; dosing utilized Calvert formula with a target AUC=7 in combination regimen with thiotepa and topotecan</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Spreafico 2008:</i> Consolidation after reinduction chemo (relapsed Wilms Tumor): Children &lt;12 years: IV: 200 mg/m<sup>2</sup> for 4 doses on days -6 to -3 in combination with melphalan and etoposide</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Glioma:</b> Limited data available (Packer 1997): Infants &ge;3 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: IV: 175 mg/m<sup>2</sup> once weekly for 4 weeks every 6 weeks (2-week recovery period between courses) in combination with vincristine for 2 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: IV: 175 mg/m<sup>2</sup> weekly for 4 weeks, with a 3-week recovery period between courses in combination with vincristine for &le;12 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuroblastoma, localized and unresectable:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: IV: 6.6 mg/<b>kg</b> on days 1, 2, and 3 in combinations with etoposide for 2 cycles (CE regimen), followed by cyclophosphamide, doxorubicin, and vincristine (CAdO regimen) (Rubie 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;10 kg: IV: 100 to 140 mg/m<sup>2</sup>/day on days 1, 2, and 3 every 21 days in combination with etoposide for 2 cycles (CE regimen), followed by cyclophosphamide, doxorubicin, and vincristine (CAdO regimen) (Rubie 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;10 kg and Adolescents: IV: 200 mg/m<sup>2</sup>/day on days 1, 2, and 3 every 21 days in combination with etoposide for 2 cycles (CE regimen), followed by cyclophosphamide, doxorubicin, and vincristine (CAdO regimen) (Rubie 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Retinoblastoma:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Rodriguez-Galindo 2003:</i> Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &ge;50 mL/minute/m<sup>2</sup>: IV: 560 mg/m<sup>2</sup> in combination with vincristine every 21 days for 8 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;50 mL/minute/m<sup>2</sup>: IV: Dosing utilized modified Calvert formula with a target AUC=6.5 in combination regimen with vincristine every 21 days for 8 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Friedman 2000: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &le;3 years: IV: 18.6 mg/<b>kg</b> on day 0 every 28 days in combination with etoposide and vincristine for 6 cycles (VEC regimen)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;3 years: IV: 560 mg/m<sup>2</sup> on day 0 every 28 days in combination with etoposide and vincristine for 6 cycles (VEC regimen)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sarcomas; Ewing sarcoma, osteosarcoma:</b> Children and Adolescents: IV: 400 mg/m<sup>2</sup>/day for 2 days every 21 days in combination with ifosfamide and etoposide (ICE regimen) (Van Winkle 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Wilms tumor, relapsed or refractory: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Abu-Ghosh 2002; Daw 2009:</i> Children and Adolescents: IV: 400 mg/m<sup>2</sup>/day for 2 days or modified Calvert using Marina/St. Jude formula with a target AUC=6 for 1 day in combination with ifosfamide and etoposide every 21 days (ICE regimen)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Spreafico 2008: </i>Reinduction prior to autologous stem cell rescue: Children &lt;12 years: IV: 600 mg/m<sup>2</sup> for 1 dose in combination with ifosfamide and etoposide</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Doses for adults are commonly calculated by the target AUC using the Calvert formula, where Total dose (mg) = Target AUC x (GFR + 25). If estimating glomerular filtration rate (GFR) instead of measuring GFR, the Food and Drug Administration (FDA) recommends considering capping estimated GFR at a maximum of 125 mL/minute to avoid potential toxicity. Dosing based on GFR should be considered in obese patients; GFR should not exceed 125 mL/minute (Griggs 2012). Carboplatin is associated with a moderate emetic potential in adult patients; antiemetics are recommended to prevent nausea and vomiting (Basch 2011; Roila 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ovarian cancer, advanced:</b> IV: 360 mg/m<sup>2</sup> every 4 weeks (as a single agent) or 300 mg/m<sup>2</sup> every 4 weeks (in combination with cyclophosphamide) or target AUC 4 to 6 mg/mL/minute (single agent; in previously treated patients). <b>Note:</b> Delay repeat doses until neutrophil count is at least 2,000 and the platelet count is at least 100,000.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult: Post-treatment nadir: Platelets &lt;50,000 cells/mm<sup>3</sup> or ANC &lt;500 cells/mm<sup>3</sup>: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: The following dosage adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &le;50 mL/minute/1.73 m<sup>2</sup>: Use modified Calvert formula (see protocol for specific details) incorporating patient's GFR</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): Use modified Calvert formula (see protocol for specific details) incorporating GFR of 33 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis, peritoneal dialysis: Use modified Calvert formula (see protocol for specific details) incorporating GFR &lt;10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: <b>Note:</b> Dose determination with Calvert formula uses GFR and, therefore, inherently adjusts for renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The manufacturer's labeling recommends the following dosage adjustment guidelines for single-agent therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Baseline CrCl &gt;59 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Baseline CrCl 41 to 59 mL/minute: Initiate at 250 mg/m<sup>2</sup> and adjust subsequent doses based on bone marrow toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Baseline CrCl 16 to 40 mL/minute: Initiate at 200 mg/m<sup>2</sup> and adjust subsequent doses based on bone marrow toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Baseline CrCl &le;15 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing adjustment: The following dosage adjustments have been used by some clinicians (for dosing based on mg/m<sup>2</sup>):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Aronoff 2007:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &gt;50 mL/minute: No dosage adjustment is necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR 10 to 50 mL/minute: Administer 50% of the dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &lt;10 mL/minute: Administer 25% of the dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous ambulatory peritoneal dialysis (CAPD): Administer 25% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous renal replacement therapy (CRRT): 200 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Janus 2010:</i> Hemodialysis: Carboplatin dose (mg) = Target AUC x 25; administer on a nondialysis day, hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, carboplatin undergoes minimal hepatic metabolism; dosage adjustment may not be needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146167\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (5 mL); 150 mg/15 mL (15 mL); 450 mg/45 mL (45 mL); 600 mg/60 mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (5 mL); 150 mg/15 mL (15 mL); 450 mg/45 mL (45 mL); 600 mg/60 mL (60 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146152\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045749\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Carboplatin is associated with a moderate emetic potential in adult patients and a high emetic potential in pediatric patients; antiemetics are recommended to prevent nausea and vomiting (Basch 2011; Dupuis 2011; Roila 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: <b>Note:</b> Needles or IV administration sets that contain aluminum should not be used in the preparation or administration of carboplatin; aluminum can react with carboplatin resulting in precipitate formation and loss of potency. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer over 15 to 60 minutes although some protocols may require infusions up to 24 hours. When administered as a part of a combination chemotherapy regimen, sequence of administration may vary by regimen; refer to specific protocol for sequence recommendation. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130923\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\"> NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146182\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at room temperature at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).  Protect from light. Further dilution to a concentration as low as 0.5 mg/mL is stable at room temperature (25&deg;C) for 8 hours in NS or D5W. Stability has also been demonstrated for dilutions in D5W in PVC bags at room temperature for 9 days (Benaji 1994); however, the manufacturer recommends use within 8 hours due to lack of preservative. Multidose vials are stable for up to 14 or 15 days after opening when stored at 25&deg;C (77&deg;F) following multiple needle entries (refer to specific product labeling for stability information).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045748\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of advanced ovarian carcinoma (FDA approved in adults); has also been used in the treatment of central nervous system tumors (gliomas, neuroblastomas), retinoblastoma, sarcomas (Ewing sarcoma, osteosarcoma), Wilms tumor, and as a conditioning regimen prior to hematopoietic stem cell transplantation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146248\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">CARBOplatin may be confused with CISplatin, oxaliplatin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Paraplatin may be confused with Platinol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Carboplatin is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 65 years and older due to its potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146244\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Neurotoxicity, pain, peripheral neuropathy </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Alopecia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, constipation, diarrhea, dysgeusia, mucositis, nausea (without vomiting), stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, bleeding complications, bone marrow depression (dose related and dose limiting; nadir at ~21 days with single-agent therapy), hemorrhage, leukopenia, neutropenia, thrombocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Decreased creatinine clearance, increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylaxis, anorexia, bronchospasm, cardiac failure, cerebrovascular accident, dehydration, embolism, erythema, febrile neutropenia, hemolytic anemia (acute), hemolytic-uremic syndrome, hypertension, hypotension, injection site reaction (pain, redness, swelling), limb ischemia (acute), malaise, metastases, pruritus, skin rash, tissue necrosis (associated with extravasation), urticaria, vision loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146174\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of severe allergic reaction to carboplatin, cisplatin, other platinum-containing formulations, mannitol, or any component of the formulation; should not be used in patients with severe bone marrow depression or significant bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146156\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b> [US Boxed Warning]: Bone marrow suppression, which may be severe, is dose related; may result in infection (due to neutropenia) or bleeding (due to thrombocytopenia); anemia may require blood transfusion.</b> Reduce dosage in patients with bone marrow suppression; cycles should be delayed until WBC and platelet counts have recovered. In patients receiving single agent carboplatin, the median nadir typically occurs at day 21. Patients who have received prior myelosuppressive therapy and patients with renal dysfunction are at increased risk for bone marrow suppression. Anemia is cumulative. Monitor blood counts closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: <b>[US Boxed Warning]: Vomiting may occur.</b> Carboplatin is associated with a moderate to high emetic potential in adult patients (dose dependent) and a high emetic potential in pediatric patients; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016). Nausea and vomiting may be more severe in patients who have received prior emetogenic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactoid reactions: <b>[US Boxed Warning]: Anaphylactic-like reactions have been reported with carboplatin; may occur within minutes of administration. Epinephrine, corticosteroids, and antihistamines have been used to treat symptoms.</b> The risk of allergic reactions (including anaphylaxis) is increased in patients previously exposed to platinum therapy. Skin testing and desensitization protocols have been reported (Confina-Cohen 2005; Lee 2004; Markman 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Liver function abnormalities: High doses (&gt;4 times the recommended dose) have resulted in severe abnormalities of liver function tests.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Although peripheral neuropathy occurs infrequently, the incidence of peripheral neuropathy is increased in patients &gt;65 years of age and those who have previously received cisplatin treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ototoxicity: Ototoxicity may occur when administered concomitantly with aminoglycosides. Clinically significant hearing loss has been reported to occur in pediatric patients when therapy was administered at higher-than-recommended doses in combination with other ototoxic agents (eg, aminoglycosides). In a study of children receiving carboplatin for the treatment of retinoblastoma, those &lt;6 months of age at treatment initiation were more likely to experience ototoxicity; long-term audiology monitoring is recommended (Qaddoumi 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: Carboplatin has a limited potential for nephrotoxicity unless administered concomitantly with aminoglycosides. Use caution with concomitant administration with aminoglycosides or other nephrotoxic medications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vision loss: Loss of vision (usually reversible within weeks of discontinuing) has been reported with higher-than-recommended doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; patients with renal dysfunction are at increased risk for bone marrow suppression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Taxane derivatives: When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before the platinum derivatives (carboplatin, cisplatin) to limit myelosuppression and to enhance efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Patients &gt;65 years of age are more likely to develop thrombocytopenia (severe) and peripheral neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dosing with Calvert formula: When calculating the carboplatin dose using the Calvert formula and an eGFR, the laboratory method used to measure serum creatinine may impact dosing. Compared to other methods, standardized isotope dilution mass spectrometry (IDMS) may underestimate serum creatinine values in patients with low creatinine values (eg, &le;0.7 mg/dL) and may overestimate GFR in patients with normal renal function. This may result in higher calculated carboplatin doses and increased toxicities. If using IDMS, the FDA recommends that clinicians consider capping estimated GFR at a maximum of 125 mL/minute to avoid potential toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46041437\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ototoxicity has been reported with platinum-based (ie, cisplatin and carboplatin) chemotherapy; the reported incidence in pediatric patients with cisplatin is 13% to 95% and is highly variable due to different assessment tools, which also affects reported severity levels and risk factor determination. In a multicenter trial of 333 patients (mean age: 4 years; range: 0.3 to 29 years; 80% of patients were &lt;5 years at time of diagnosis) treated for high-risk neuroblastoma with cisplatin induction therapy followed by an HSCT myeloablative regimen which included carboplatin in some patients (ie, multiple-exposure), audiological evaluations (including baseline) were completed using multiple assessment tools. At the time of evaluation, the majority of patients were &lt;5 years of age at time of initial exposure and results showed some degree of hearing loss in &ge;64% of patients following single exposure (cisplatin induction) and &gt;80% of those with multiple-exposure (cisplatin induction plus carboplatin myeloablation) regardless of grading scale. Overall, the hearing loss was graded as moderate or severe in 41% to 85% of patients depending on the scale with a higher incidence (66% to 85%) in those with who received both cisplatin induction and carboplatin myeloablation; &gt;50% required a hearing aid (Landier 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298973\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146161\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13117&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bexarotene (Systemic): CARBOplatin may increase the serum concentration of Bexarotene (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: Platinum Derivatives may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: May enhance the adverse/toxic effect of CARBOplatin. Management: Concurrent sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.  Use in other settings is not specifically contraindicated but should be approached with added caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146163\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10923584\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045744\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, serum electrolytes, serum creatinine and BUN, nuclear medicine measured GFR or creatinine clearance, liver function tests; audiology evaluations in pediatric patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146155\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links. Carboplatin is apparently not cell-cycle specific.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146173\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 16 L (based on a dose of 300 to 500 mg/m<sup>2</sup>); into liver, kidney, skin, and tumor tissue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Carboplatin: 0%; Platinum (from carboplatin): Irreversibly binds to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimally hepatic to aquated and hydroxylated compounds </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: CrCl &gt;60 mL/minute: Carboplatin: 2.6 to 5.9 hours (based on a dose of 300 to 500 mg/m<sup>2</sup>); Platinum (from carboplatin): &ge;5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~70% as carboplatin within 24 hours; 3% to 5% as platinum within 1 to 4 days)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323041\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CARBOplatin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (5 mL): $12.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/15 mL (15 mL): $28.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 mg/45 mL (45 mL): $78.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/60 mL (60 mL): $86.04</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146176\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actoplatin (ID, PH);</li>\n      <li>Adcarb (LK);</li>\n      <li>B-Platin (BR);</li>\n      <li>Bagotanilo (MX);</li>\n      <li>Balidon (CO);</li>\n      <li>Biocarb (IN);</li>\n      <li>Biovinate (PH);</li>\n      <li>Biplatinex (VE);</li>\n      <li>Blastocarb (CL, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Blastocarb RU (MX);</li>\n      <li>Bobei (CN);</li>\n      <li>Bocartin (VN);</li>\n      <li>Bopacatin (SK);</li>\n      <li>Boplatex (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Carbopa (MY);</li>\n      <li>Carboplat (AR, BD, DE, MX);</li>\n      <li>Carboplatin (AE, AU, CY, DK, IL, JO, KW, LB, LT, NO, NZ, PL, SA);</li>\n      <li>Carboplatin a (PT);</li>\n      <li>Carboplatin Abic (TH);</li>\n      <li>Carboplatin DBL (MY);</li>\n      <li>Carboplatin dbl (PT);</li>\n      <li>Carboplatin &ldquo;Delta West&rdquo; (HR);</li>\n      <li>Carboplatin-David Bull (LU);</li>\n      <li>Carboplatin-Medac (LU);</li>\n      <li>Carboplatin-Teva (HU);</li>\n      <li>Carboplatino (CU);</li>\n      <li>Carboplatinum Cytosafe-Delta West (LU);</li>\n      <li>Carbosin (BE, GR, ID, KR, LU, PH, ZW);</li>\n      <li>Carbosin Lundbeck (FI);</li>\n      <li>Carbotec (MX);</li>\n      <li>Carbotin (BD);</li>\n      <li>Carbotinol (PH, SA);</li>\n      <li>Carcan (ID);</li>\n      <li>Carplan (KR);</li>\n      <li>Cobalmin (PE);</li>\n      <li>Cycloplatin (CZ, HU);</li>\n      <li>Cytocarb (LB);</li>\n      <li>Delta West Carboplatin (ID, PH);</li>\n      <li>Karbopa (UA);</li>\n      <li>Kemocarb (ID, JO, LK, PH, SG, TH, TW, VN, ZW);</li>\n      <li>Kemokarb (UA);</li>\n      <li>Megaplatin (LB);</li>\n      <li>Naproplat (PH);</li>\n      <li>Neoplatin (KR);</li>\n      <li>Nuvaplast (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Omilipis (AR, PY);</li>\n      <li>Oncocarb (PE);</li>\n      <li>Oncocarbin (IN);</li>\n      <li>P&amp;U Carboplatin (ZA);</li>\n      <li>Paraplatin (AT, BE, BG, CH, EC, EE, EG, ES, FI, FR, GB, HK, HN, HR, HU, IE, IT, JO, LU, NL, PH, PT, QA, RU, SE, TH, TR, TW, UY);</li>\n      <li>Pharmaplatin (PK);</li>\n      <li>Unicarb (LK);</li>\n      <li>Vancel (BR, PY);</li>\n      <li>Womaplat (LK);</li>\n      <li>Womastin (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abramson DH, Frank CM, and Dunkel IJ, &ldquo;A Phase I/II Study of Subconjunctival Carboplatin for Intraocular Retinoblastoma,&rdquo; <i>Ophthalmology</i>, 1999, 106(10):1947-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/10519590/pubmed\" target=\"_blank\" id=\"10519590\">10519590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. <i>Ann Oncol</i>. 2002;13(3):460-469.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11996479 /pubmed\" target=\"_blank\" id=\"11996479 \">11996479 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allen S, Wilson MW, Watkins A, et al. Comparison of two methods for carboplatin dosing in children with retinoblastoma. <i>Pediatr Blood Cancer</i>. 2010;55(1):47-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20486170/pubmed\" target=\"_blank\" id=\"20486170\">20486170</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span><span class=\"doi\">10.1200/JCO.2010.34.4614</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benaji B, Dine T, Luyckx M, et al. Stability and compatibility of cisplatin and carboplatin with PVC infusion bags. <i>J Clin Pharm Ther</i>. 1994;19(2):95-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/8071399/pubmed\" target=\"_blank\" id=\"8071399\">8071399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cairo MS, &ldquo;The Use of Ifosfamide, Carboplatin, and Etoposide in Children With Solid Tumors,&rdquo; <i>Semin Oncol</i>, 1995, 22(3 Suppl 7):23-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/7610395/pubmed\" target=\"_blank\" id=\"7610395\">7610395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calvert AH, Newell DR, Grumbell LA, et al, &ldquo;Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function,&rdquo; <i>J Clin Oncol</i>, 1989, 7(11):1748-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/2681557/pubmed\" target=\"_blank\" id=\"2681557\">2681557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carboplatin [prescribing information]. Rockford, IL: Mylan Institutional LLC; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheung Y-W, Cradock JC, Vishnuvajjala BR, et al, &quot;Stability of Cisplatin, Iproplatin, Carboplatin, and Tetraplatin in Commonly Used Intravenous Solutions,&quot; <i>Am J Hosp Pharm</i>, 1987, 44:124-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/3548341/pubmed\" target=\"_blank\" id=\"3548341\">3548341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen BH, Geyer JR, Miller DC, et al. Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 phase I/II study. A report from the Children's Oncology Group. <i>Pediatr Neurol</i>. 2015;53(1):31-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/26092413 /pubmed\" target=\"_blank\" id=\"26092413 \">26092413 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Confino-Cohen R, Fishman A, Altaras M, et al, &ldquo;Successful Carboplatin Desensitization in Patients With Proven Carboplatin Allergy,&rdquo; <i>Cancer</i>, 2005, 104(3):640-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15977213/pubmed\" target=\"_blank\" id=\"15977213\">15977213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daw NC, Gregornik D, Rodman J, et al. Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour. <i>Eur J Cancer</i>. 2009;45(1):99-106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18996004 /pubmed\" target=\"_blank\" id=\"18996004 \">18996004 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. <i>J Clin Oncol</i>. 2000;18(1):12-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/10623688 /pubmed\" target=\"_blank\" id=\"10623688 \">10623688 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilheeney SW, Khakoo Y, Souweidane M, et al, &quot;Thiotepa/Topotecan/Carboplatin With Autologous Stem Cell Rescue in Recurrent/Refractory/Poor Prognosis Pediatric Malignancies of the Central Nervous System,&quot; <i>Pediatr Blood Cancer</i>, 2010, 54(4):591-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/19998470/pubmed\" target=\"_blank\" id=\"19998470\">19998470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2012;30(13):1553-1561.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/22473167 /pubmed\" target=\"_blank\" id=\"22473167 \">22473167 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Ann Oncol</i>. 2010;21(7):1395-1403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20118214 /pubmed\" target=\"_blank\" id=\"20118214 \">20118214 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Cheung NK, Kramer K, Dunkel IJ, Calleja E, Boulad F. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. <i>Bone Marrow Transplant</i>. 2001;28(6):551-556.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11607767/pubmed\" target=\"_blank\" id=\"11607767\">11607767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Landier W, Knight K, Wong FL, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2014;32(6):527-534.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/24419114 /pubmed\" target=\"_blank\" id=\"24419114 \">24419114 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CW, Matulonis UA, and Castells MC, &ldquo;Carboplatin Hypersensitivity: A 6-h 12-Step Protocol Effective in 35 Desensitizations in Patients With Gynecological Malignancies and Mast Cell/IgE-Mediated Reactions,&rdquo; <i>Gynecol Oncol</i>, 2004, 95(2):370-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15491759/pubmed\" target=\"_blank\" id=\"15491759\">15491759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liem RI, Higman MA, Chen AR, Arceci RJ. Misinterpretation of a Calvert-derived formula leading to carboplatin overdose in two children. <i>J Pediatr Hematol Oncol</i>. 2003;25(10):818-821.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/14528109 /pubmed\" target=\"_blank\" id=\"14528109 \">14528109 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lovett D, Kelsen D, Eisenberger M, et al, &ldquo;A Phase II Trial of Carboplatin and Vinblastine in the Treatment of Advanced Squamous Cell Carcinoma of the Esophagus,&rdquo; <i>Cancer</i>, 1991, 67(2):354-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/1985729/pubmed\" target=\"_blank\" id=\"1985729\">1985729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. <i>J Clin Oncol.</i> 2000;18(22):3809-3818.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11078494/pubmed\" target=\"_blank\" id=\"11078494\">11078494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mann JR, Raafat F, Robinson K, et al. UKCCSG's germ cell tumour (GCT) studies: improving outcome for children with malignant extracranial non-gonadal tumours--carboplatin, etoposide, and bleomycin are effective and less toxic than previous regimens. United Kingdom Children's Cancer Study Group. <i>Med Pediatr Oncol</i>. 1998;30(4):217-227.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/9473756/pubmed\" target=\"_blank\" id=\"9473756\">9473756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marina NM, Rodman J, Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. <i>J Clin Oncol</i>. 1993;11(3):554-560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/8445431/pubmed\" target=\"_blank\" id=\"8445431\">8445431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Markman M, Zanotti K, Peterson G, et al, &ldquo;Expanded Experience With an Intradermal Skin Test to Predict for the Presence or Absence of Carboplatin Hypersensitivity,&rdquo; <i>J Clin Oncol</i>, 2003, 21(24):4611-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/14673050/pubmed\" target=\"_blank\" id=\"14673050\">14673050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newell DR, Pearson AD, Balmanno K, et al, &ldquo;Carboplatin Pharmacokinetics in Children: The Development of a Pediatric Dosing Formula. The United Kingdom Children's Cancer Study Group,&rdquo; <i>J Clin Oncol</i>, 1993, 11(12):2314-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/8246021/pubmed\" target=\"_blank\" id=\"8246021\">8246021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Packer RJ, Ater J, Allen J, et al, &ldquo;Carboplatin and Vincristine Chemotherapy for Children With Newly Diagnosed Progressive Low-Grade Gliomas,&rdquo; <i>J Neurosurg</i>, 1997, 86(5):747-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/9126887/pubmed\" target=\"_blank\" id=\"9126887\">9126887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearson AD, Pinkerton CR, Lewis IJ, et al, &quot;High-Dose Rapid and Standard Induction Chemotherapy for Patients Aged Over 1 Year With Stage 4 Neuroblastoma: A Randomised Trial,&quot; <i>Lancet Oncol</i>, 2008, 9(3):247-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18308250/pubmed\" target=\"_blank\" id=\"18308250\">18308250</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pein F, Michon J, Valteau-Couanet D, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study.<i> J Clin Oncol</i>. 1998;16(10):3295-3301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/9779704/pubmed\" target=\"_blank\" id=\"9779704\">9779704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pein F, Tournade MF, Zucker JM, et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor--a phase II study by the French Society of Pediatric Oncology. <i>J Clin Oncol</i>. 1994;12(5):931-936.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/8164044 /pubmed\" target=\"_blank\" id=\"8164044 \">8164044 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qaddoumi I, Bass JK, Wu J, et al, &ldquo;Carboplatin-Associated Ototoxicity in Children With Retinoblastoma,&rdquo; <i>J Clin Oncol</i>, 2012, 30(10):1034-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/22370329/pubmed\" target=\"_blank\" id=\"22370329\">22370329</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. <i>J Clin Oncol</i>. 2003;21(10):2019-2025.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/12743157 /pubmed\" target=\"_blank\" id=\"12743157 \">12743157 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubie H, Michon J, Plantaz D, et al. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique (SFOP). <i>Br J Cancer</i>. 1998;77(12):2310-2317.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/9649151/pubmed\" target=\"_blank\" id=\"9649151\">9649151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubie H, Plantaz D, Coze C, et al. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique. <i>Med Pediatr Oncol</i>. 2001;36(1):247-250.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11464897 /pubmed\" target=\"_blank\" id=\"11464897 \">11464897 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spreafico F, Bisogno G, Collini P, et al. Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology. <i>Pediatr Blood Cancer</i>. 2008;51(1):23-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18293386/pubmed\" target=\"_blank\" id=\"18293386\">18293386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Winkle P, Angiolillo A, Krailo M, et al, &ldquo;Ifosfamide, Carboplatin, and Etoposide (ICE) Reinduction Chemotherapy in a Large Cohort of Children and Adolescents With Recurrent/Refractory Sarcoma: The Children&rsquo;s Cancer Group (CCG) Experience,&rdquo; <i>Pediatr Blood Cancer</i>, 2005, 44(4):338-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15503297/pubmed\" target=\"_blank\" id=\"15503297\">15503297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeltzer PM, Epport K, Nelson MD Jr, et al, &ldquo;Prolonged Response to Carboplatin in an Infant With Brain Stem Glioma,&rdquo; <i>Cancer</i>, 1991, 67(1):43-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/1985722/pubmed\" target=\"_blank\" id=\"1985722\">1985722</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13117 Version 159.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708661\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F146189\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045745\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045738\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F146167\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F146152\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045749\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130923\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F146182\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045748\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F146248\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F146244\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F146174\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F146156\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F46041437\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298973\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F146161\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F146163\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10923584\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045744\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F146155\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F146173\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323041\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F146176\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13117|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">Carboplatin: Drug information</a></li><li><a href=\"topic.htm?path=carboplatin-patient-drug-information\" class=\"drug drug_patient\">Carboplatin: Patient drug information</a></li></ul></div></div>","javascript":null}